PERCEPTIVE ADVISORS LLC
Q1 2023 13F-HR/A Holdings
Net value change ($000)
-174,175
(-4.9%)
New positions
19
Sold out positions
15
Turnover %
20.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| REATA PHARMACEUTICALS INC | 197,231 | NEW |
| OBIO | 44,585 | NEW |
| SNY | 41,800 | NEW |
| ACLX | 37,869 | 47.0% |
| APLS | 36,630 | NEW |
| NTRA | 34,043 | 651.9% |
| ALDX | 33,709 | 42.7% |
| IOVA | 30,006 | 47.1% |
| CymaBay Therapeutics, Inc. | 29,591 | 665.7% |
| PTGX | 22,198 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Horizon Therapeutics Public Ltd Co | -109,248 | -100.0% |
| VRNA | -72,638 | -57.0% |
| MDGL | -54,838 | -25.8% |
| SRPT | -48,176 | -57.3% |
| AMLX | -47,908 | -21.3% |
| Cerevel Therapeutics Holdings, Inc. | -46,529 | -22.7% |
| Mirati Therapeutics, Inc. | -40,767 | -41.1% |
| BDQM | -37,972 | -100.0% |
| BELLUS Health Inc. | -37,426 | -51.2% |
| VERU | -36,504 | -88.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
7,621
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|